scholarly journals Macrophage activation syndrome in a newborn infant born to a mother with autoimmune disease

2015 ◽  
Vol 35 (2) ◽  
pp. 158-160 ◽  
Author(s):  
J H Park ◽  
S H Kim ◽  
H J Kim ◽  
S J Lee ◽  
D C Jeong ◽  
...  
Keyword(s):  
Autoimmune Disease ◽  
Newborn Infant ◽  
Macrophage Activation Syndrome ◽  
Macrophage Activation ◽  
Activation Syndrome

scholarly journals Etoposide as an Effective Drug for Adult Macrophage Activation Syndrome: A Retrospective Study

2021 ◽  
Author(s):  
Lingbo He ◽  
Zhili Jin ◽  
Menghan Liu ◽  
Tingting Cui ◽  
Lin Wu ◽  
...  
Keyword(s):  
Autoimmune Disease ◽  
Initial Treatment ◽  
Macrophage Activation Syndrome ◽  
Macrophage Activation ◽  
Hemophagocytic Syndrome ◽  
Response Rate ◽  
Initial Therapy ◽  
Group 2 ◽  
Activation Syndrome ◽  
Group 1

Abstract BackgroundAutoimmune disease related hemophagocytic syndrome, in other words, macrophage activation syndrome(MAS), is a rare, but lethal complication of autoimmune disease. At present, specific treatment guidelines for adult MAS have not been formulated, most experience are derived from children, researches about etoposide are scarce. As the importance of etoposide in the initial treatment had been proved in other subtypes of hemophagocytic syndrome, the objective of this study is to investigate the effectiveness of etoposide in the treatment of the adult macrophage activation syndrome.Result74 patients with autoimmune disease related hemophagocytic syndrome were involved in this study, they were divided into two groups based on initial treatment, group 1(n=53): initial therapy did not contain etoposide, group 2(n=21): initial therapy contained etoposide. The overall response rate and complete response rate of group 2 were significantly higher than group 1(ORR 90.5% vs 24.5%, CRR 33.3% vs 3.8%, P<0.05). Patients with different HLH remission states have significantly different prognosis(P<0.001).ConclusionAdopting VP-16 in initial treatment can significantly increase the OR rate and CR rate of adult MAS patients, and the HLH states influenced the prognosis significantly.

scholarly journals Macrophage Activation Syndrome in Autoimmune Disease

2010 ◽  
Vol 153 (2) ◽  
pp. 109-120 ◽  
Author(s):  
Sean Deane ◽  
Carlo Selmi ◽  
Suzanne S. Teuber ◽  
M. Eric Gershwin
Keyword(s):  
Autoimmune Disease ◽  
Macrophage Activation Syndrome ◽  
Macrophage Activation ◽  
Activation Syndrome

scholarly journals Macrophage activation syndrome in a newborn infant born to a untreated mother with adult onset still disease

2014 ◽  
Vol 12 (S1) ◽  
Author(s):  
Jung Woo Rhim ◽  
Soo Young Lee ◽  
Joo Hyung Park ◽  
Soon Joo Lee ◽  
So Young Kim ◽  
...  
Keyword(s):  
Newborn Infant ◽  
Macrophage Activation Syndrome ◽  
Macrophage Activation ◽  
Adult Onset ◽  
Still Disease ◽  
Activation Syndrome

scholarly journals Macrophage Activation Syndrome Presented in a Case of Neonatal Lupus

2021 ◽  
Vol 28 (3) ◽  
pp. 139-142
Author(s):  
Chang Min Kang ◽  
Jinwha Choi ◽  
JungHwa Lee
Keyword(s):  
Autoimmune Disease ◽  
Autoimmune Diseases ◽  
Macrophage Activation Syndrome ◽  
Macrophage Activation ◽  
Early Recognition ◽  
Transplacental Passage ◽  
Neonatal Lupus ◽  
Life Threatening ◽  
Life Threatening Complication ◽  
Activation Syndrome

Macrophage activation syndrome (MAS) is a potentially life-threatening complication in many autoimmune diseases. Early recognition and intervention are essential for a favorable outcome. Neonatal lupus, an acquired autoimmune disease in neonates caused by the transplacental passage of maternal autoantibodies, is rare and usually self-limited. Herein, we report a case of MAS in a patient with neonatal lupus, which improved with intravenous immunoglobulin.

Sign in / Sign up

Export Citation Format

Share Document